Arcellx, Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $51.34 |
| Prev. Close | $50.69 |
| EPS | -2.65 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 14, 2023 |
| Dividend Yield % | - |
| Market Cap | $2.55B |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 50.73 | 53.53 |
| 52 Week Range | 18.70 | 56.09 |
| Ratios | |
|---|---|
| P/B Ratio | 6.12 |
| Revenue | $47.17M |
| Operating M. % | -299.94% |
| Earnings | -$129.52M |
| Earnings Growth % | - |
| EBITDA Margin % | -303.47% |
| ROE % | -51.56% |
| EPS | -2.65 |
Score Breakdown
All Score (57 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| ACLX | Market | |
|---|---|---|
| Value | 13 | 42 |
| Quality | 43 | 46 |
| Ownership | 78 | 39 |
| Growth | 78 | 44 |
| Dividends | - | 32 |
All Score (57 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Arcellx, Inc. (ACLX)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Rami Elghandour
- Headquarters
- Gaithersburg
- Employees
- 98
Keep an eye on Arcellx, Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.